Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety StudyRomosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
- Other Titles
- Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
- Authors
- 백기현; 정윤석; 고정민; 김인주; 김경민; 민용기; 박기덕; Rajani Dinavahi; Judy Maddox; Wenjing Yang; 김수아; 이상진; 조형진; 임승길
- Issue Date
- Feb-2021
- Publisher
- 대한내분비학회
- Keywords
- Bone density; Bone turnover markers; Korea; Randomized controlled trial; Romosozumab; Adrenal gland neoplasms; Adrenalectomy; Laparoscopy; Organ preservation
- Citation
- Endocrinology and Metabolism, v.36, no.1, pp.60 - 69
- Journal Title
- Endocrinology and Metabolism
- Volume
- 36
- Number
- 1
- Start Page
- 60
- End Page
- 69
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80548
- DOI
- 10.3803/EnM.2020.848
- ISSN
- 2093-596X
- Abstract
- Background: This phase 3 study evaluated the efficacy and safety of 6-month treatment with romosozumab in Korean postmenopausal women with osteoporosis.
Methods: Sixty-seven postmenopausal women with osteoporosis (bone mineral density [BMD] T-scores ≤–2.5 at the lumbar spine, total hip, or femoral neck) were randomized (1:1) to receive monthly subcutaneous injections of romosozumab (210 mg; n=34) or placebo (n=33) for 6 months.
Results: At month 6, the difference in the least square (LS) mean percent change from baseline in lumbar spine BMD (primary efficacy endpoint) between the romosozumab (9.5%) and placebo (–0.1%) groups was significant (9.6%; 95% confidence interval, 7.6 to 11.5; P<0.001). The difference in the LS mean percent change from baseline was also significant for total hip and femoral neck BMD (secondary efficacy endpoints). After treatment with romosozumab, the percent change from baseline in procollagen type 1 Nterminal propeptide transiently increased at months 1 and 3, while that in C-terminal telopeptide of type 1 collagen showed a sustained decrease. No events of cancer, hypocalcemia, injection site reaction, positively adjudicated atypical femoral fracture or osteonecrosis of the jaw, or positively adjudicated serious cardiovascular adverse events were observed. At month 9, 17.6% and 2.9% ofpatients in the romosozumab group developed binding and neutralizing antibodies, respectively.
Conclusion: Treatment with romosozumab for 6 months was well tolerated and significantly increased lumbar spine, total hip, and femoral neck BMD compared with placebo in Korean postmenopausal women with osteoporosis (ClinicalTrials.gov identifier NCT02791516).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80548)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.